{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:43:57Z","timestamp":1762004637216,"version":"3.40.4"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0101760","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T17:19:46Z","timestamp":1405099186000},"page":"e101760","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV\/HCV Coinfected Patients"],"prefix":"10.1371","volume":"9","author":[{"given":"Sara","family":"Corchado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Torres-Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"M\u00e1rquez-Coello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Antonio","family":"Gir\u00f3n-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-2005-864780","article-title":"Treatment of chronic hepatitis C in human immunodeficiency virus\/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin","volume":"25","author":"N Br\u00e4u","year":"2005","journal-title":"Semin Liver Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","article-title":"A new standard of care for treatment of chronic HCV infection","volume":"8","author":"WP Hofmann","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MCG.0000000000000010","article-title":"Hepatitis C Direct-acting Antiviral Agents. Changing the paradigm of hepatitis C treatment in HIV-infected patients","volume":"48","author":"V Martel-Laferriere","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"M Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy With Telaprevir for chronic hepatitis C virus genotype 1 infection in patients With HIV: A Randomized trial","volume":"159","author":"MS Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dieterich D, Rockstroh JK, Orkin C, Gutierrez F, Klein M, et al. (2013) Simeprevir (TMC435) with peginterferon\/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3\u20136, abstract 154LB.","DOI":"10.1093\/cid\/ciu675"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/infdis\/jis764","article-title":"Current management of hepatitis C virus infection in patients with HIV co-infection","volume":"207","author":"MS Sulkowski","year":"2013","journal-title":"J Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/COH.0b013e32834b54dc","article-title":"Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions","volume":"6","author":"K Seden","year":"2011","journal-title":"Current Opinion on HIV and AIDS"},{"key":"ref9","unstructured":"Naggie S, Sulkowski M, Lalezari J, Fessel J, Mounzer K, et al. (2014) Sofosbuvir Plus Ribavirin for HCV Genotype 1\u20133 Infection in HIV Coinfected Patients (PHOTON-1). 21th Conference on Retroviruses and Opportunistic Infections, Boston, USA, March 3\u20136, Abstract 26."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/656235","article-title":"Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus","volume":"51","author":"JA Pineda","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/QAD.0b013e3283568884","article-title":"Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients","volume":"26","author":"JA Mira","year":"2012","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/135965350701200805","article-title":"Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients","volume":"12","author":"JA Mira","year":"2007","journal-title":"Antivir Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\/HCV-coinfected patients receiving ribavirin","volume":"9","author":"A Moreno","year":"2004","journal-title":"Antivir Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"A Kau","year":"2008","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"M Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"8963","DOI":"10.3748\/wjg.v19.i47.8963","article-title":"Antiviral treatment of hepatitis C virus infection and factors affecting efficacy","volume":"19","author":"Y Zhu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02934504","article-title":"Molecular mechanisms of hepatic fibrosis and principles of therapy","volume":"32","author":"SL Friedman","year":"1997","journal-title":"J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/jhep.2003.50127","article-title":"Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal","volume":"37","author":"R Bataller","year":"2003","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e66619","DOI":"10.1371\/journal.pone.0066619","article-title":"Influence of Genetic Polymorphisms of Tumor Necrosis Factor Alpha and Interleukin 10 Genes on the Risk of Liver Cirrhosis in HIV-HCV Coinfected Patients","volume":"8","author":"S Corchado","year":"2013","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"14467","DOI":"10.1073\/pnas.97.26.14467","article-title":"Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10","volume":"97","author":"HD Shin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cyto.2003.10.005","article-title":"IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection","volume":"25","author":"A Mangia","year":"2004","journal-title":"Cytokine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gut.2005.065904","article-title":"Prediction of liver fibrosis in HIV\/HCV-coinfected patients by simple noninvasive indexes","volume":"55","author":"J Mac\u00edas","year":"2006","journal-title":"Gut"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/cit103","article-title":"Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus-coinfected patients with compensated cirrhosis","volume":"56","author":"JA Mira","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0b013e3282f1da99","article-title":"Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C","volume":"22","author":"L Martin-Carbonero","year":"2008","journal-title":"AIDS"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/656811","article-title":"Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV","volume":"51","author":"J Medrano","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.clinthera.2012.08.009","article-title":"Boceprevir: a protease inhibitor for the treatment of hepatitis C","volume":"34","author":"MH Chang","year":"2012","journal-title":"Clin Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/11208370-000000000-00000","article-title":"Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C","volume":"72","author":"CM Perry","year":"2012","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2893.2005.00710.x","article-title":"Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-3b plus ribavirin in HCV genotypes 1\/4 according to HIV serostatus","volume":"13","author":"A Moreno","year":"2006","journal-title":"J Viral Hep"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jhep.2011.11.008","article-title":"Prediction of response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load","volume":"56","author":"K Neukam","year":"2012","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jinf.2013.03.010","article-title":"Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response","volume":"67","author":"K Neukam","year":"2013","journal-title":"J Infect"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkr439","article-title":"Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV\/HCV co-infected patients with genotype 1 or 4","volume":"67","author":"A Rivero-Juarez","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"AJ Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients","volume":"24","author":"NI Rallon","year":"2010","journal-title":"AIDS"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1478-3231.2011.02709.x","article-title":"Phase III results in genotype 1 na\u0131ve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin","volume":"32","author":"PY Kwo","year":"2012","journal-title":"Liver Int"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1525-1578(10)60585-5","article-title":"Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels","volume":"7","author":"E Rodriguez-Inigo","year":"2005","journal-title":"J Mol Diagn"},{"key":"ref36","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (2014) Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis cr\u00f3nica C (VHC) en pacientes monoinfectados. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/criterios-VHC-monoinfectados_28-02-12.pdf\" xlink:type=\"simple\">http:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/criterios-VHC-monoinfectados_28-02-12.pdf<\/ext-link>. Accessed 2014 Mar 1."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jhep.2012.11.013","article-title":"Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure","volume":"58","author":"GR Foster","year":"2013","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0b013e318061b5d9","article-title":"Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV\/HCV-coinfected patients","volume":"45","author":"M N\u00fa\u00f1ez","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"F Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAD.0b013e328012b5ba","article-title":"Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3 \/ HIV co-infected patients","volume":"21","author":"M Crespo","year":"2000","journal-title":"AIDS"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/gut.2006.106690","article-title":"Rapid and early virological response to chronic hepatitis C treatment with IFN alfa2b or PEG-IFN alfa 2b plus ribavirin in HIV \/ HCV coinfected patients","volume":"56","author":"C Payan","year":"2007","journal-title":"Gut"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1097\/01.aids.0000432460.44593.ef","article-title":"The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV\/HCV-coinfected patients","volume":"27","author":"M Mandorfer","year":"2013","journal-title":"AIDS"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"M Laguno","year":"2004","journal-title":"AIDS"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/088922204323048096","article-title":"Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients","volume":"20","author":"V Soriano","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22311","article-title":"Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C","volume":"48","author":"JR Jonsson","year":"2008","journal-title":"Hepatology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/jir.1998.18.705","article-title":"Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C","volume":"18","author":"C Fabris","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/00365520510011470","article-title":"Adhesion molecules as a prognostic marker of liver cirrhosis","volume":"40","author":"JA Gir\u00f3n-Gonz\u00e1lez","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2893.2005.00679.x","article-title":"Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin","volume":"13","author":"E Mar\u00edn-Serrano","year":"2006","journal-title":"J Viral Hepat"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0101760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T19:38:07Z","timestamp":1746301087000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0101760"}},"subtitle":[],"editor":[{"given":"Wenyu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0101760","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2014,7,11]]}}}